Boehringer Ingelheim and MD Anderson join forces to discover new treatment approaches for pancreatic cancer
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC).
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Pancreas | Pancreatic Cancer | Texas University